Treatment of Drug Dependence and Psychiatric Illness

描述：（申请人提供） 此K 02竞争续签申请的主要目的是进一步推动 申请人？药物依赖治疗领域的科学发展 患者，特别是那些被“双重诊断”滥用药物的患者， 同时存在精神疾病。两个主要假设指导申请人？S 目前和计划的研究。第一，由于药物依赖性和双重性， 确诊患者是一个异质性组，确定有意义的亚组 针对这些亚组的特定治疗将改善 治疗结果第二个主要假设是， 不同的治疗方法（例如，药物治疗和 精神疗法）可以改善对药物依赖患者的治疗。这 申请是为了加强申请人？参与五 作为PI或合作研究者资助的项目。以下是获资助的项目 申请人目前正在追求：1）NIDA行为疗法 发展项目，比较两种不同形式的团体治疗， 双相情感障碍和物质依赖患者（DA 09400，PI）; 2）a 多中心随机对照试验，评价以下药物联合治疗： 酒精依赖的药物治疗和行为治疗 （AA 11756，研究中心PI）; 3）检查可卡因遗传学的多中心研究 依赖（DA 12849，研究中心PI）; 4）NIDA资助的项目， CDP-胆碱治疗可卡因依赖的功效（DA 11098， 共同研究者）;和5）一个多中心NIMH资助的项目，以检查最佳 双相情感障碍患者的治疗，申请人将 检查对那些同时存在物质使用障碍的患者的治疗方法 （MH 80001，物质滥用途径负责人和合作研究者）。申请人 建议通过学习更多的遗传学知识来扩展他的研究能力 和统计方法。最后，申请人将 指导年轻的研究人员在他们的药物滥用研究生涯，并为 作为NIDA治疗研究IRG的评审员， 参加全国性的成瘾问题组织和编辑委员会 期刊

DESCRIPTION: (provided by the applicant) The primary aim of this K02 competing renewal application is to further the applicant?s scientific development in the area of treatment of drug dependent patients, particularly those who are "dually diagnosed" with drug abuse and coexisting psychiatric illness. Two major hypotheses guide the applicant?s current and planned research. The first is that since drug dependent and dually diagnosed patients are a heterogeneous group, identifying meaningful subgroups of patients and targeting specific therapies to these subgroups will improve treatment outcome. The second major hypothesis is that studying the integration of different treatment approaches (e.g., the combination of pharmacotherapy and psychotherapy) can lead to improved treatment for drug dependent patients. This application is designed to strengthen the applicant?s involvement in five funded projects as PI or Co-Investigator. The following funded projects are currently being pursued by the applicant: 1) a NIDA Behavioral Therapies Development Project to compare two different forms of group therapy for patients with bipolar disorder and substance dependence (DA09400, PI); 2) a multi-site randomized controlled trial evaluating combinations of pharmacotherapy and behavioral therapies in the treatment of alcohol dependence (AA11756, Site PI); 3) a multi-site study examining the genetics of cocaine dependence (DA12849, Site PI); 4) a NIDA-funded project examining the potential efficacy of CDP-choline in the treatment of cocaine dependence (DA11098, Co-Investigator); and 5) a multicenter NIMH-funded project to examine optimal treatments for individuals with bipolar disorder, for which the applicant will examine treatments for those patients with coexisting substance use disorder (MH80001, Substance Abuse Pathway Leader and Co-Investigator). The applicant proposes to expand his research capabilities by learning more about genetics and statistical methods through guided tutorials. Finally, the applicant will mentor younger investigators in their drug abuse research careers and serve the field in general through work as a reviewer on the NIDA Treatment Research IRG and participation in national organizations and editorial boards of addiction journals.